Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Raajit Rampai"'
Autor:
Gozde Colak, Vikas Gupta, Andrea Patriarca, John Mascarenhas, Patricia J. Keller, James Shao, Claire N. Harrison, Nikki Granacher, Gary J. Schiller, Tim C. P. Somervaille, Moshe Talpaz, Jonathan Lambert, Katarina Luptakova, Srdan Verstovsek, Raajit Rampai, Ronald Hoffman, Linda Foltz, Prithviraj Bose, Marina Kremyanskaya, Alessandro M. Vannucchi, Witold Prejzner, Mark Drummond
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S361-S362
Context: Pelabresib (CPI-0610), a first-in-class, oral, small-molecule inhibitor of BET proteins, has the potential to promote disease-modifying activity through altered gene regulation of key oncogenic, fibrotic, and inflammatory factors in MF. Many
Autor:
Jing Wang, Oksana Zavidij, Srdan Verstovsek, Horatiu Olteanu, Dong Chen, Patrick Trojer, Patricia J. Keller, Claire N. Harrison, Moshe Talpaz, Katarina Luptakova, Gozde Colak, April Chiu, Mohamed E. Salama, Jike Cui, Curtis A. Hanson, Raajit Rampai, John Mascarenhas, Alessandro M. Vannucchi, Ruben A. Mesa, Zehua Chen, Stephen T. Oh, Jennifer A. Mertz, Jeffrey S. Humphrey
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S363-S364
Context: Pelabresib (CPI-0610) is a potent, selective BET bromodomain inhibitor under investigation in the ongoing Phase 2 MANIFEST trial, given as monotherapy to ruxolitinib (rux)-intolerant/refractory myelofibrosis (MF) pts in arm 1, as an “add-o